Invivo imaging of MMP-13 activity in the murine destabilised medial meniscus surgical model of osteoarthritis

Osteoarthritis and Cartilage

Volumn 22, Issue 6, 2014, Pages 862-868

  Lim, N H ^a   Meinjohanns, E ^b   Meldal, M ^c   Bou Gharios, G ^a   Nagase, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARLSBERG LABORATORY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Imaging; MMP 13; Osteoarthritis

Indexed keywords

COLLAGENASE 3; MACROPHAGE ELASTASE; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUORESCENCE IMAGING; HISTOPATHOLOGY; IN VIVO STUDY; KNEE SURGERY; MALE; MOLECULAR PROBE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; ANIMAL; AUDIOVISUAL EQUIPMENT; C57BL MOUSE; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DISEASE MODEL; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; KNEE; KNEE OSTEOARTHRITIS; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURGERY; TIME;

ANIMALS; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; KNEE JOINT; MALE; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED C57BL; MODELS, ANATOMIC; OSTEOARTHRITIS, KNEE; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84901841135     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.04.006     Document Type: Article

References (20)

1. Binks D.A., Hodgson R.J., Ries M.E., Foster R.J., Smye S.W., McGonagle D., et al. Quantitative parametric MRI of articular cartilage: a review of progress and open challenges. Br J radiology 2013, 86:20120163.
2. Illingworth K.D., El Bitar Y., Siewert K., Scaife S.L., El-Amin S., Saleh K.J. Correlation of WOMAC and KOOS scores to tibiofemoral cartilage loss on plain radiography and 3 Tesla MRI: data from the osteoarthritis initiative. Knee Surg Sports Traumatol Arthrosc 2013, 10.1007/s00167-013-2402-6.
3. Hoch J.M., Mattacola C.G., Medina McKeon J.M., Howard J.S., Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage 2011, 19:1396-1404.
4. Mobasheri A. Osteoarthritis year 2012 in review: biomarkers. Osteoarthritis Cartilage 2012, 20:1451-1464.
5. Settle S., Vickery L., Nemirovskiy O., Vidmar T., Bendele A., Messing D., et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010, 62:3006-3015.
6. Troeberg L., Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta 2012, 1824:133-145.
7. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
8. Little C.B., Barai A., Burkhardt D., Smith S.M., Fosang A.J., Werb Z., et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733.
9. Kozawa E., Nishida Y., Cheng X.W., Urakawa H., Arai E., Futamura N., et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. Arthritis Rheum 2012, 64:454-464.
10. Edgington L.E., Verdoes M., Bogyo M. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol 2011, 15:798-805.
11. Lim N.H., Meinjohanns E., Bou-Gharios G., Gompels L.L., Nuti E., Rossello A., et al. Invivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis. Arthritis Rheum 2014, 66:589-598.
12. Chia S.L., Sawaji Y., Burleigh A., McLean C., Inglis J., Saklatvala J., et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheum 2009, 60:2019-2027.
13. Glasson S.S., Chambers M.G., Van Den Berg W.B., Little C.B. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010, 18(Suppl 3):S17-S23.
14. Glasson S.S., Blanchet T.J., Morris E.A. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 2007, 15:1061-1069.
15. Lee S., Park K., Lee S.Y., Ryu J.H., Park J.W., Ahn H.J., et al. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development invivo. Bioconjugate Chem 2008, 19:1743-1747.
16. Lampropoulou-Adamidou K., Lelovas P., Karadimas E.V., Liakou C., Triantafillopoulos I.K., Dontas I., et al. Useful animal models for the research of osteoarthritis. Eur J Orthop Surg Traumatol 2014, 24:263-271.
17. Pratta M.A., Yao W., Decicco C., Tortorella M.D., Liu R.Q., Copeland R.A., et al. Aggrecan protects cartilage collagen from proteolytic cleavage. JBiol Chem 2003, 278:45539-45545.
18. Maroudas A., Bayliss M.T., Uchitel-Kaushansky N., Schneiderman R., Gilav E. Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Archives Biochem Biophys 1998, 350:61-71.
19. Maroudas A., Palla G., Gilav E. Racemization of aspartic acidinhuman articular cartilage. Connect Tissue Res 1992, 28:161-169.
20. Little C.B., Hunter D.J. Post-traumatic osteoarthritis: from mousemodels to clinical trials. Nat Rev Rheumatol 2013, 9:485-497.